<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519063</url>
  </required_header>
  <id_info>
    <org_study_id>1005006779</org_study_id>
    <secondary_id>P50AA012870</secondary_id>
    <nct_id>NCT01519063</nct_id>
  </id_info>
  <brief_title>Naltrexone and Memantine Effects on Alcohol Drinking Behaviors</brief_title>
  <official_title>Glutamate-opioid Interactions in Alcohol Drinking Behaviors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the combined effects of the study medications
      naltrexone and memantine on alcohol drinking behaviors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive a combination of naltrexone/memantine over a one
      week period and then participate in a laboratory session. During this session, participants
      are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks
      over a three-hour period. These medications are hypothesized to reduce craving and number of
      drinks consumed prior to and after exposure to the initial drink of alcohol and during the
      three hour drinking period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">May 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 29, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Drinks Consumed at Lab Session (Day 7)</measure>
    <time_frame>Day 7</time_frame>
    <description>Number of drinks consumed during the lab session (Day 7) after taking study medication, ranging from 0-12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Craving AUC: Adlib Drinking Phase</measure>
    <time_frame>50-230 minutes after the priming drink during lab session</time_frame>
    <description>Craving for alcohol based on Alcohol Urge Questionnaire (AUQ, Bohn et al., 1995), which is an 8 item measurement of self-reported alcohol urges that has been shown to be strongly related to alcohol dependence severity. Each item is scored from 1 (strongly disagree) to 7 (strongly agree), with a higher score indicating higher craving. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Higher craving scores (ranging from 0-56) are indicated by larger log-transformed AUC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stimulation Response to Alcohol at Lab Session</measure>
    <time_frame>50-230 minutes after the priming drink during lab session</time_frame>
    <description>Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Higher stimulation scores (ranging from 0-70) are indicated by larger log-transformed AUC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedation Response to Alcohol at Lab Session</measure>
    <time_frame>50-230 minutes after the priming drink during lab session</time_frame>
    <description>Brief Biphasic Alcohol Effects Scale-Sedation subscale (BAES; Martin et al., 1993), measuring sedation effects of alcohol. The seven items included on the sedation subscale range from 1 (not at all) to extremely (10) with higher measurements indicating higher sedation. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Area Under the Curve was used to calculate the final score reported for the BAES.
As a single summary measure, AUC, was calculated for BAES outcomes based on scores recorded at numerous time points throughout the adlib drinking session The calculation was based on the trapezoidal methods using times 50, 90, 110, 150, 170, 210, and 230 . Based on the distribution, each AUC was log-transformed. Higher AUC levels correspond to greater levels of sedation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Craving AUC: Priming Dose Phase</measure>
    <time_frame>0-50 minutes after the priming drink</time_frame>
    <description>Craving for alcohol based on Alcohol Urge Questionnaire (AUQ, Bohn et al., 1995), which is an 8 item measurement of self-reported alcohol urges that has been shown to be strongly related to alcohol dependence severity. Each item is scored from 1 (strongly disagree) to 7 (strongly agree), with a higher score indicating higher craving. Craving for alcohol based on Alcohol Urge Questionnaire is calculated using Area Under the Curve (AUC). A single summary measure, AUC was calculated for AUQ outcomes based on scores recorded at numerous time points throughout the priming drink session. The calculation was based on the trapezoidal methods using times -20, 10, 20, 30, 40, 50 minutes before/after priming drink. Based on the distribution, each AUC was log-transformed. Higher AUC levels correspond to greater alcohol urge.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sedation Response to Alcohol: Priming Dose Phase</measure>
    <time_frame>0-50 minutes after priming drink</time_frame>
    <description>Brief Biphasic Alcohol Effects Scale-Sedation subscale, measuring sedation effects of alcohol with higher measurements indicating higher sedation. Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. The subscale total range is 0-70, these scores are logged transformed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stimulation Response to Alcohol: Priming Dose Phase</measure>
    <time_frame>0-50 minutes after priming drink</time_frame>
    <description>Brief Biphasic Alcohol Effects Scale-Stimulation subscale, measuring stimulation effects of alcohol with higher measurements indicating higher stimulation. Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. The subscale total range is 0-70, these scores are logged transformed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>Naltrexone and memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Naltrexone and memantine first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with naltrexone and placebo first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and memantine first</intervention_name>
    <description>Naltrexone 50mg memantine 20mg</description>
    <arm_group_label>Naltrexone and Placebo</arm_group_label>
    <arm_group_label>Naltrexone and memantine</arm_group_label>
    <other_name>memantine's brand name is Namenda</other_name>
    <other_name>naltrexone's brand name is Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone and Placebo first</intervention_name>
    <description>Naltrexone 50 mg Placebo</description>
    <arm_group_label>Naltrexone and Placebo</arm_group_label>
    <arm_group_label>Naltrexone and memantine</arm_group_label>
    <other_name>naltrexone's brand name is Revia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 21-55

          -  Able to read English at 6th grade level or higher and to complete study evaluations

          -  Regular alcohol drinker

        Exclusion Criteria:

          -  Individuals who are seeking alcohol treatment

          -  Medical conditions that would contraindicate the use of study medication

          -  Regular use of other substances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchitra Krishnan-Sarin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sac, Cmhc</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <results_first_submitted>June 29, 2018</results_first_submitted>
  <results_first_submitted_qc>June 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2019</results_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Drinking</keyword>
  <keyword>Drinkers</keyword>
  <keyword>Alcohol Drinking</keyword>
  <keyword>Memantine</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcohol Abuse</keyword>
  <keyword>Alcohol-Related Disorders</keyword>
  <keyword>Ethanol</keyword>
  <keyword>Alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Drinking Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT01519063/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The number of participants enrolled was 75. However, 19 people did not start medication due to ineligibility or drop out, leaving 56 total participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone and Memantine First</title>
          <description>Patients received Naltrexone and Memantine first in this arm.</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone and Placebo First</title>
          <description>Patients received Naltrexone and Placebo first in this arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone and Memantine First</title>
          <description>Patients in this arm received Naltrexone and Memantine first.</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone and Placebo First</title>
          <description>Patients in this arm received Naltrexone and Placebo first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="8.5"/>
                    <measurement group_id="B2" value="33" spread="9.3"/>
                    <measurement group_id="B3" value="33" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Number of Caucasian and Non-Caucasian participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total number of drinks over past 90 days</title>
          <description>Timeline Followback (TLFB; Sobell &amp; Sobell, 1996)</description>
          <units>drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166" spread="63"/>
                    <measurement group_id="B2" value="165" spread="1"/>
                    <measurement group_id="B3" value="165" spread="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks per drinking day in past 90 days</title>
          <units>drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="2.5"/>
                    <measurement group_id="B2" value="7.2" spread="2.9"/>
                    <measurement group_id="B3" value="7.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent of drinking days over past 90 days</title>
          <units>percent of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="16"/>
                    <measurement group_id="B2" value="75" spread="17"/>
                    <measurement group_id="B3" value="76" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Drinks Consumed at Lab Session (Day 7)</title>
        <description>Number of drinks consumed during the lab session (Day 7) after taking study medication, ranging from 0-12.</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Memantine</title>
            <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Drinks Consumed at Lab Session (Day 7)</title>
          <description>Number of drinks consumed during the lab session (Day 7) after taking study medication, ranging from 0-12.</description>
          <units>drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="4.19"/>
                    <measurement group_id="O2" value="5.02" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Craving AUC: Adlib Drinking Phase</title>
        <description>Craving for alcohol based on Alcohol Urge Questionnaire (AUQ, Bohn et al., 1995), which is an 8 item measurement of self-reported alcohol urges that has been shown to be strongly related to alcohol dependence severity. Each item is scored from 1 (strongly disagree) to 7 (strongly agree), with a higher score indicating higher craving. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Higher craving scores (ranging from 0-56) are indicated by larger log-transformed AUC.</description>
        <time_frame>50-230 minutes after the priming drink during lab session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Memantine</title>
            <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Craving AUC: Adlib Drinking Phase</title>
          <description>Craving for alcohol based on Alcohol Urge Questionnaire (AUQ, Bohn et al., 1995), which is an 8 item measurement of self-reported alcohol urges that has been shown to be strongly related to alcohol dependence severity. Each item is scored from 1 (strongly disagree) to 7 (strongly agree), with a higher score indicating higher craving. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Higher craving scores (ranging from 0-56) are indicated by larger log-transformed AUC.</description>
          <units>log (units on a scale * minutes)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" spread=".54"/>
                    <measurement group_id="O2" value="7.75" spread=".55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stimulation Response to Alcohol at Lab Session</title>
        <description>Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Higher stimulation scores (ranging from 0-70) are indicated by larger log-transformed AUC.</description>
        <time_frame>50-230 minutes after the priming drink during lab session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Memantine</title>
            <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Stimulation Response to Alcohol at Lab Session</title>
          <description>Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Higher stimulation scores (ranging from 0-70) are indicated by larger log-transformed AUC.</description>
          <units>log (units on a scale *minutes)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="3.51"/>
                    <measurement group_id="O2" value="4.93" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sedation Response to Alcohol at Lab Session</title>
        <description>Brief Biphasic Alcohol Effects Scale-Sedation subscale (BAES; Martin et al., 1993), measuring sedation effects of alcohol. The seven items included on the sedation subscale range from 1 (not at all) to extremely (10) with higher measurements indicating higher sedation. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Area Under the Curve was used to calculate the final score reported for the BAES.
As a single summary measure, AUC, was calculated for BAES outcomes based on scores recorded at numerous time points throughout the adlib drinking session The calculation was based on the trapezoidal methods using times 50, 90, 110, 150, 170, 210, and 230 . Based on the distribution, each AUC was log-transformed. Higher AUC levels correspond to greater levels of sedation.</description>
        <time_frame>50-230 minutes after the priming drink during lab session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Memantine</title>
            <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Response to Alcohol at Lab Session</title>
          <description>Brief Biphasic Alcohol Effects Scale-Sedation subscale (BAES; Martin et al., 1993), measuring sedation effects of alcohol. The seven items included on the sedation subscale range from 1 (not at all) to extremely (10) with higher measurements indicating higher sedation. Assessed multiple times, starting at 50 minutes after priming drink until 230 minutes after priming drink. Area Under the Curve was used to calculate the final score reported for the BAES.
As a single summary measure, AUC, was calculated for BAES outcomes based on scores recorded at numerous time points throughout the adlib drinking session The calculation was based on the trapezoidal methods using times 50, 90, 110, 150, 170, 210, and 230 . Based on the distribution, each AUC was log-transformed. Higher AUC levels correspond to greater levels of sedation.</description>
          <units>log (units on a scale *minutes)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" spread="2.97"/>
                    <measurement group_id="O2" value="5.34" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Craving AUC: Priming Dose Phase</title>
        <description>Craving for alcohol based on Alcohol Urge Questionnaire (AUQ, Bohn et al., 1995), which is an 8 item measurement of self-reported alcohol urges that has been shown to be strongly related to alcohol dependence severity. Each item is scored from 1 (strongly disagree) to 7 (strongly agree), with a higher score indicating higher craving. Craving for alcohol based on Alcohol Urge Questionnaire is calculated using Area Under the Curve (AUC). A single summary measure, AUC was calculated for AUQ outcomes based on scores recorded at numerous time points throughout the priming drink session. The calculation was based on the trapezoidal methods using times -20, 10, 20, 30, 40, 50 minutes before/after priming drink. Based on the distribution, each AUC was log-transformed. Higher AUC levels correspond to greater alcohol urge.</description>
        <time_frame>0-50 minutes after the priming drink</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Memantine</title>
            <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Craving AUC: Priming Dose Phase</title>
          <description>Craving for alcohol based on Alcohol Urge Questionnaire (AUQ, Bohn et al., 1995), which is an 8 item measurement of self-reported alcohol urges that has been shown to be strongly related to alcohol dependence severity. Each item is scored from 1 (strongly disagree) to 7 (strongly agree), with a higher score indicating higher craving. Craving for alcohol based on Alcohol Urge Questionnaire is calculated using Area Under the Curve (AUC). A single summary measure, AUC was calculated for AUQ outcomes based on scores recorded at numerous time points throughout the priming drink session. The calculation was based on the trapezoidal methods using times -20, 10, 20, 30, 40, 50 minutes before/after priming drink. Based on the distribution, each AUC was log-transformed. Higher AUC levels correspond to greater alcohol urge.</description>
          <units>log (units on a scale *minutes)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.81" spread=".55"/>
                    <measurement group_id="O2" value="6.84" spread=".57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sedation Response to Alcohol: Priming Dose Phase</title>
        <description>Brief Biphasic Alcohol Effects Scale-Sedation subscale, measuring sedation effects of alcohol with higher measurements indicating higher sedation. Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. The subscale total range is 0-70, these scores are logged transformed.</description>
        <time_frame>0-50 minutes after priming drink</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Memantine</title>
            <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Response to Alcohol: Priming Dose Phase</title>
          <description>Brief Biphasic Alcohol Effects Scale-Sedation subscale, measuring sedation effects of alcohol with higher measurements indicating higher sedation. Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. The subscale total range is 0-70, these scores are logged transformed.</description>
          <units>log (units on a scale)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="2.49"/>
                    <measurement group_id="O2" value="3.76" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stimulation Response to Alcohol: Priming Dose Phase</title>
        <description>Brief Biphasic Alcohol Effects Scale-Stimulation subscale, measuring stimulation effects of alcohol with higher measurements indicating higher stimulation. Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. The subscale total range is 0-70, these scores are logged transformed.</description>
        <time_frame>0-50 minutes after priming drink</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Memantine</title>
            <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Placebo</title>
            <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Stimulation Response to Alcohol: Priming Dose Phase</title>
          <description>Brief Biphasic Alcohol Effects Scale-Stimulation subscale, measuring stimulation effects of alcohol with higher measurements indicating higher stimulation. Brief Biphasic Alcohol Effects Scale-Stimulation subscale (BAES; Martin et al., 1993), measuring stimulation effects of alcohol. Seven items ranging from 0 (not at all) to extremely (10) with higher measurements indicating higher stimulation. The subscale total range is 0-70, these scores are logged transformed.</description>
          <units>log (units on a scale)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="2.84"/>
                    <measurement group_id="O2" value="3.43" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected at baseline and during the 7 days of medication, as well as at the one week follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone and Memantine</title>
          <description>Treatment with Naltrexone and memantine
Naltrexone and memantine: Naltrexone 50mg memantine 20mg</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone and Placebo</title>
          <description>Treatment with naltrexone and placebo
Naltrexone and Placebo: Naltrexone 50 mg Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dana Cavallo, Assistant Professor</name_or_title>
      <organization>Yale University</organization>
      <phone>203974-7607</phone>
      <email>dana.cavallo@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

